Physician profile
Eric Christenson
NPI 1043553456
$10,437.14
in general payments reported to CMS, 2019-2025
11 companies · $6,891 in 2025
The $6,891 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,872 · 2024: $675 · 2025: $6,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,988 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Food and Beverage: $422 · Travel and Lodging: $28.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,987.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Food and Beverage | $421.64 |
| Travel and Lodging | $28.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,765.50 | 2025 | Intera |
| Sirtex Medical INC | $2,709.61 | 2023 | Sir-Spheres Microspheres |
| Roche Sequencing Solutions, INC. | $1,000.00 | 2025 | |
| Urogen Pharma, INC. | $675.00 | 2024 | |
| Musculoskeletal Transplant Foundation INC. | $162.03 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2025 | Fruzaqla |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Christenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.